Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup

Evaluation of Amyloid Imaging in People with Metabolic Disorder Identified by Brain FDG-PET as Part of a Complete Medical Checkup - Amyloid Imaging in Medical Checkup

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011612

Enrollment

100

Registered

2013-10-01

Start date

2014-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study population will consist of people who have a special cancer screening (whole-body FDG-PET) at the Preventive Medicine Center and consent to undergo cognitive function tests and brain FDG-PET.

Exclusion criteria

Exclusion criteria: Disagree

Design outcomes

Primary

Measure	Time frame
Each 30 subjects who have abnormal metabolism on an FDG-PET scan and positive amyloid PET (stage 2 preclinical AD) and those who have abnormal metabolism on an FDG-PET scan and normal amyloid PET (which may represent non-preclinical AD but suggest other neurological disease) will be monitored for a long term to assess changes in clinical features and cognitive function over time.	—

Countries

Japan

Contacts

Public ContactDaisuke Ito

School of medicine, Keio University Department of neurology

d-ito@jk9.so-net.ne.jp+81-3-5363-3788

Outcome results